Inhibikase Therapeutics Inc
NASDAQ:IKT
Intrinsic Value
Inhibikase Therapeutics, Inc. provides infectious disease treatments. [ Read More ]
The intrinsic value of one
IKT
stock under the Base Case scenario is
10.22
USD.
Compared to the current market price of 1.9 USD,
Inhibikase Therapeutics Inc
is
Undervalued by 81%.
Inhibikase Therapeutics Inc's market capitalization is 11.8m USD.
IKT stock price is 1.9 USD.
IKT stock price (1.9 USD) is 81% less than its Intrinsic Value (10.22 USD).
IKT. Open DCF Valuation
IKT.
IKT's Revenue has grown by an exceptional 117% over the past 12 months.
IKT's ROE (Return on Equity) has significantly increased in the last 3 years from -296% to -119%, and is approaching profitability.
IKT's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -1 195% to -2 981%, and is approaching profitability.
IKT has negative Operating Income for the last twelve months.
IKT has negative Net Income for the last twelve months.
IKT's ROE (Return on Equity) for the past 12 months is negative and is equal to -119%.
IKT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -2 981%.
IKT's Revenue is forecast to grow at a rate of 222% per year over the next 3 years.
IKT's Revenue has been falling by 28% per year for the last 3 years.
IKT has negative Free Cash Flow for the last twelve months.
IKT has negative three-year average ROE (Return on Equity): -85%. The company is not efficient at transforming stockholders' equity into net income.
IKT has negative three-year average ROIC (Return on Invested Capital): -663%. The company is not efficient at using invested capital to generate operating income.
IKT's short-term assets (14m USD) exceed its short-term liabilties (3m USD).
IKT's long-term assets (15m USD) exceed its long-term liabilties (4m USD).
IKT's D/E (Debt to Equity) is very low and is equal to 0.
IKT's Altman Z-Score is very low and is equal to -9.88.
Valuation Backtest
Inhibikase Therapeutics Inc
Run backtest to discover the historical profit from buying and selling
IKT
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Inhibikase Therapeutics Inc
Balance Sheet Decomposition
Inhibikase Therapeutics Inc
| Current Assets | 14.2m |
| Cash & Short-Term Investments | 13.3m |
| Other Current Assets | 959k |
| Non-Current Assets | 295.6k |
| PP&E | 295.6k |
| Current Liabilities | 3.4m |
| Accounts Payable | 646.8k |
| Accrued Liabilities | 2.4m |
| Other Current Liabilities | 381.8k |
| Non-Current Liabilities | 90.1k |
| Other Non-Current Liabilities | 90.1k |
Earnings Waterfall
Inhibikase Therapeutics Inc
|
Revenue
|
260.5k
USD
|
|
Operating Expenses
|
-20.4m
USD
|
|
Operating Income
|
-20.1m
USD
|
|
Other Expenses
|
1.1m
USD
|
|
Net Income
|
-19m
USD
|
Free Cash Flow Analysis
Inhibikase Therapeutics Inc
IKT Profitability Score
Profitability Due Diligence
Inhibikase Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Inhibikase Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
IKT Solvency Score
Solvency Due Diligence
Inhibikase Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Inhibikase Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IKT Price Targets Summary
Inhibikase Therapeutics Inc
Ownership
IKT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
IKT Price
Inhibikase Therapeutics Inc
| Average Annual Return | -57.72% |
| Standard Deviation of Annual Returns | 24.69% |
| Max Drawdown | -99% |
| Market Capitalization | 11.8m USD |
| Shares Outstanding | 6 566 840 |
| Percentage of Shares Shorted | 0.36% |
Company Profile
Inhibikase Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Inhibikase Therapeutics, Inc. provides infectious disease treatments. The company is headquartered in Atlanta, Georgia and currently employs 6 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The firm's product candidates include IkT-148009, IkT-001pro, and IKT-01427. Its lead product candidate, IkT-148009 is for the treatment of PD and for the treatment of gastrointestinal (GI), complications that arise as early symptoms of PD in patients. The Company’s kT-148009 is a brain penetrant c-Abl protein kinase inhibitor that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract. Its product candidate IkT-001Pro, is a prodrug of the anticancer agent Imatinibm, and used as a treatment for chronic myelogenous leukemia (CML). IkT-01427 is an oral, brain-penetrant medication , designed to block the entry of the JC virus into the cell, thereby preventing the virus’ ability to replicate in the body.
Contact
IPO
Employees
Officers
The intrinsic value of one
IKT
stock under the Base Case scenario is
10.22
USD.
Compared to the current market price of 1.9 USD,
Inhibikase Therapeutics Inc
is
Undervalued by 81%.
You don't have any saved screeners yet
